Member Info for Krone

Sierra Oncology to Attend Two Investor Conferences in May VANCOUVER, May 6, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that members of its senior management team will be attending the SunTrust Robinson Humphrey 5th Annual Life Sciences Conference in New York on May 8th, and the Oppenheimer Oncology Insight Summit in New York on May 16th. Sun Trust Robinson Humphrey 5th Annual Life Sciences Summit Date: May 8 Format: One-on-one sessions Oppenheimer Oncology Insight Summit Date: May 16 Format: One-on-one sessions About Sierra Oncology Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Our lead drug candidate, momelotinib, is a potent, selective and orally-bioavailable JAK1, JAK2 and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a potentially differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control. Sierra Oncology is also advancing SRA737 and SRA141. SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DNA Damage Response (DDR). SRA737 is currently being investigated in two Phase 1/2 clinical trials: SRA737-01, a monotherapy study, and SRA737-02, a drug combination study evaluating SRA737 potentiated by non-cytotoxic low dose gemcitabine. Sierra Oncology has also prepared for a potential clinical study of SRA737 in combination with a PARP inhibitor. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7). Cdc7 is a key regulator of DNA replication and is involved in the DDR network, making it a compelling emerging target for the potential treatment of a broad range of tumor types. For more information, please visit www.sierraoncol

However, Sareum include VEGFR-3 in the SKIL platform so this could be a potential further string to the already well strung bow! VEGFR-3 kinase VEGFR-3 (Vascular Endothelial Growth Factor Receptor 3 Kinase), also known at FLT4, is involved in the generation of new blood and lymph vessels to a tumour. It is often over produced in many different types of cancer including: lung gastric prostate Lymph vessels are known to be a major route of metastasis. Inhibitors of VEGFR-3 therefore have the potential to reduce, delay or inhibit the spread of cancer throughout the body. We have discovered a series of compounds that demonstrate potent inhibition of lymph cell growth by selectively inhibiting VEGFR-3.

Sareum has retweeted as below, which must be hugely significant!!!! $LLY Q1 PPT appears to show discontinuation of Chk1 inhib prexasertib. If true, could be a major +ve for $SRRA (and originator $SAR.l/@sareumplc) which has only competitor in SRA737.

And Sierra SRA737 abstract published on 15 May...

As highlighted by Thoth2, extract from BMS update: ....regarding TYK2, I think you pointed out, this is a compound that we're extremely excited about. As you know, it's a drug which looks like it has activity both through the Type I interferons as well as the IL-12/IL-23 pathways. We were delighted to see the data that we saw in psoriasis and we look forward to seeing those Phase 3 trials continue to mature. We also think this is an agent that could have benefit in inflammatory bowel disease and we're beginning studies in inflammatory bowel disease in that setting. We do have a Phase 2 study in lupus, which is appearing. I think one thing to keep in mind with lupus is, how challenging of a disease lupus has been. And I think we saw that this year, with some notable shortcomings in other trials. It's a very difficult disease to treat. It's also a very heterogeneous disease in terms of what defines the disease and what drives the disease. And so the purpose of the steroid taper is to be able to have a more objective look at the potential for the benefit of TYK2 versus the potential for the benefit of the steroid interaction. So it's really trying to reduce the number of variables that are present in an inherently variable disease.

Can we afford to wait 8 months and potentially miss the Tyk2 boat?

Abstract summaries should be published on 15 May.

#DYK? The Janus Kinases (Jaks) are named after the Roman god of duality because they have two adjacent domains. Tyk2, one of our targets, is a member of the Jak family. Learn about our work to inhibit Tyk2 activity: bit.ly/2TVKWZ1

Seems Parker has regurgitated the same old spiel and managed to convince another BoD of his superlative skills set! https://wcsecure.weblink.com.au/pdf/MXC/02085750.pdf Unfortunately absolutely no evidence whatsoever of any value to Sareum thus far! I hope he proves the sceptics wrong.

Sierra - don’t have to wait until 1 June for presentation....ASCO abstract due to be published 15 May https://meetings.asco.org/am/abstract-submission This should give further clarity on the potential for SRA737....

1st June

Sierra Oncology (NASDAQ:SRRA) (Sareums Chk1 licensee), has now been confirmed on the ASCO (American Society of Clinical Oncology) website as a presenter at the forthcoming ASCO annual meeting. $SAR.l @Sareumplc meetinglibrary.asco.org/record/175777/

Thanks Thoth, noted re limits, will review! Happy Easter and thanks for sharing your insights.

Over a quid?

Dr Triparna Sen @MDAndersonNews reports that the combination of Chk1 inhibitor SRA737 (originally discovered by Sareum and @ICR_London)+ LDG with immune checkpoint blockade completely regressed SCLC tumours in mouse models https://ecancer.org/video/7768/efficacy-and-immune-correlates-of-the-sra737-plus-ldg-regimen-in-combination-with-anti-pd-l1-in-an-sclc-model.php … $SAR.L #Chk1 #AIM #biotech

Thanks Ahfam

Paulus47...could you repost please...I can’t see your last???

Suspicion...wishful thinking...I hope you are right...I have only been in SAR since 2012...what a bloody grind!

for long enough the green bars appear to move to the right!! http://www.sareum.com/discovery/overview/

Apologies if this has already been highlighted. Orm123 in his post of 1st April reports that whilst he is pain free with stable PSA he has new bone mets and concludes that the 'trial has not worked'. This must be incredibly disappointing for him. Hopefully the new trial to which he is signed up will be more successful. Not good news for SRA737 either!